{
  "title": "A new step toward ending 'the wrath of malaria'",
  "description": "Scientists have been trying to figure out how to eradicate malaria for decades. Globally, a child under the age of five dies from the disease every two minutes, and even for kids who do survive there can be long term complications. A big breakthrough finally came in October when the World Health Organization endorsed MoSQUIRIX, the first malaria vaccine. It has relatively low efficacy, just about 30%, but malaria researcher <a href=\"https://twitter.com/WinterOkoth\">Winter Okoth</a> explains how the new vaccine could still make a big difference. ",
  "pubDate": "Tue, 02 Nov 2021 00:10:27 -0400",
  "copyright": "Copyright 2019-2021 NPR - For Personal Use Only",
  "guid": "aca33a1e-e4f0-4791-8dcc-f2550cb1fa79",
  "link": "https://www.npr.org/2021/11/01/1051108740/a-new-step-toward-ending-the-wrath-of-malaria",
  "itunes:title": "A new step toward ending 'the wrath of malaria'",
  "itunes:episode": 518,
  "itunes:author": "NPR",
  "itunes:summary": "A new vaccine has a relatively low efficacy. Could it still make a big difference?",
  "itunes:subtitle": "A new vaccine has a relatively low efficacy. Could it still make a big difference?",
  "itunes:image": "",
  "itunes:duration": 656,
  "itunes:explicit": "no",
  "itunes:episodeType": "full",
  "content:encoded": "Scientists have been trying to figure out how to eradicate malaria for decades. Globally, a child under the age of five dies from the disease every two minutes, and even for kids who do survive there can be long term complications. A big breakthrough finally came in October when the World Health Organization endorsed MoSQUIRIX, the first malaria vaccine. It has relatively low efficacy, just about 30%, but malaria researcher <a href=\"https://twitter.com/WinterOkoth\">Winter Okoth</a> explains how the new vaccine could still make a big difference. ",
  "enclosure": ""
}